RBC Capital analyst Sean Dodge lowered the firm’s price target on Health Catalyst (HCAT) to $7 from $9 and keeps a Sector Perform rating on the shares. The company’s outlook update included a mixed Q4 preliminary update and more precise 2025 guidance, the analyst tells investors in a research note, adding that the company is targeting revenue and EBITDA for the year at 2% below consensus and in line, respectively. While the firm is encouraged by the bookings outlook, it is looking to see these flow to revenue before getting more constructive with its rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst to Acquire Upfront Healthcare Services
- Health Catalyst to acquire Upfront Healthcare Services, terms not disclosed
- Health Catalyst price target lowered to $10 from $10.50 at Citi
- Health Catalyst upgraded to Overweight from Sector Weight at KeyBanc
- Health Catalyst price target raised to $12 from $11 at Piper Sandler